{"id":3535,"date":"2025-06-21T22:43:24","date_gmt":"2025-06-21T22:43:24","guid":{"rendered":"https:\/\/www.europesays.com\/us\/3535\/"},"modified":"2025-06-21T22:43:24","modified_gmt":"2025-06-21T22:43:24","slug":"study-finds-glp-1-drug-cut-migraine-frequency-by-nearly-half","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/3535\/","title":{"rendered":"Study finds GLP-1 drug cut migraine frequency by nearly half"},"content":{"rendered":"

GLP-1 drugs could treat more than just diabetes and obesity. They may also reduce migraine frequency.<\/p>\n

That is according to the findings of a study presented on Friday at the European Academy of Neurology congress. The pilot study<\/a> found that GLP-1 agonists reduced monthly migraine days by almost half. The authors hypothesized that the drug lowers migraine frequency by reducing intracranial pressure.<\/p>\n

\u201cIt\u2019s a hugely interesting and very important study, and it opens all sorts of questions about how the drug works,\u201d said Alexandra Sinclair, chair of the neurology department at the University of Birmingham. She was not involved in the study but has previously researched the agonists\u2019 role in reducing intracranial pressure.<\/p>\n

STAT+ Exclusive Story<\/p>\n

Already have an account? Log in<\/a><\/p>\n

\t\t\t\"STAT+\"\/<\/p>\n

\t\t\t\t\t
\n\t\t\t\t\t\t\"STAT+\"\/
\n\t\t\t\t\t<\/a><\/p>\n

\t\t\t\tThis article is exclusive to STAT+ subscribers
\n\t\t\t\tUnlock this article \u2014 plus in-depth analysis, newsletters, premium events, and news alerts.<\/p>\n

Already have an account? Log in<\/a><\/p>\n

\t\t\t\t\t\tIndividual plans<\/p>\n

\t\t\t\t\t\tGroup plans<\/p>\n

\t\t\t\tView All Plans<\/a><\/p>\n

\n\t\t\t\t\t\tTo read the rest of this story subscribe to STAT+.\t\t\t\t\t<\/p>\n

\t\t\t\t\tSubscribe<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"GLP-1 drugs could treat more than just diabetes and obesity. They may also reduce migraine frequency. That is…\n","protected":false},"author":3,"featured_media":3536,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[3738,3654,210,154,67,132,68],"class_list":{"0":"post-3535","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-health","8":"tag-clinical-trials","9":"tag-glp-1","10":"tag-health","11":"tag-stat","12":"tag-united-states","13":"tag-unitedstates","14":"tag-us"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/114723776298111257","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/3535","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=3535"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/3535\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/3536"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=3535"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=3535"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=3535"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}